fentaNYL Citrate Injectable Solution — Class II drug recall D-0503-2026
Ongoing recall by Wells Pharma of Houston LLC, reported 2026-05-06, distributed nationwide. cGMP deviations.
| Recall number | D-0503-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Wells Pharma of Houston LLC, Houston, TX, United States |
| Recall initiated | 2026-04-01 |
| Classified | 2026-04-28 |
| Reported by FDA | 2026-05-06 |
| Distributed | Nationwide (US) |
| Quantity | 4,030 iv |
| Reason classes | cgmp |
| NDC | 73702-0202-02 |
| Expiration dates | 2026-04-09, 2026-05-05, 2026-05-14, 2026-05-20, 2026-05-28, 2026-06-04, 2026-06-20, 2026-06-24 |
Product
fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells Pharma in Houston, NDC 73702-202-02.
Reason for recall
cGMP deviations.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0503-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.